TLR3 binding agents
US9388246B2 · kind B2 · utility
7Cited by
21References
55Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 5, 2011 |
| Grant date | Jul 12, 2016 |
| Priority date | — |
| Expiry date | Sep 10, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.